Emergent BioSolutions Inc.
EBS
$10.09
-$0.40-3.81%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -22.74% | -18.56% | -0.54% | 2.05% | 2.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.74% | -18.56% | -0.54% | 2.05% | 2.79% |
| Cost of Revenue | -49.47% | -11.13% | -7.23% | 3.90% | 7.84% |
| Gross Profit | 78.02% | -32.10% | 20.28% | -2.78% | -12.63% |
| SG&A Expenses | -29.35% | -22.57% | -16.06% | -9.04% | -8.71% |
| Depreciation & Amortization | 0.15% | 0.62% | -0.76% | -3.42% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.66% | -13.84% | -9.47% | -0.31% | 2.57% |
| Operating Income | 168.02% | -573.00% | 65.41% | 21.60% | -1.10% |
| Income Before Tax | 132.99% | 88.85% | 80.46% | 76.99% | -7.17% |
| Income Tax Expenses | 475.28% | 919.12% | 62.80% | -2.26% | -85.71% |
| Earnings from Continuing Operations | 123.76% | 76.72% | 74.94% | 73.16% | 2.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 123.76% | 76.72% | 74.94% | 73.16% | 2.44% |
| EBIT | 168.02% | -573.00% | 65.41% | 21.60% | -1.10% |
| EBITDA | 484.52% | -54.98% | 203.02% | 260.98% | -67.89% |
| EPS Basic | 123.23% | 76.89% | 75.68% | 73.83% | 5.90% |
| Normalized Basic EPS | 121.95% | -31.57% | 23.88% | -10.65% | -2.36% |
| EPS Diluted | 121.77% | 75.41% | 74.97% | 73.16% | 5.95% |
| Normalized Diluted EPS | 120.07% | -37.16% | 23.88% | -10.65% | -2.36% |
| Average Basic Shares Outstanding | 3.55% | 3.73% | 3.67% | 3.55% | 3.89% |
| Average Diluted Shares Outstanding | 6.14% | 6.34% | 4.89% | 4.79% | 3.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |